Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Shin BH et al. | Regulation of anti-HLA antibody-dependent natural killer cell activation by immunosuppressive agents. | 2014 | Transplantation | pmid:24342979 |
Yoon SH et al. | CYP3A and ABCB1 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of tacrolimus and its metabolites (M-I and M-III). | 2013 | Transplantation | pmid:23364483 |
Koneru B et al. | Blood transfusions in liver recipients: a conundrum or a clear benefit in the cyclosporine/tacrolimus era? | 1997 | Transplantation | pmid:9197350 |
Lawsin L and Light JA | Severe acute renal failure after exposure to sirolimus-tacrolimus in two living donor kidney recipients. | 2003 | Transplantation | pmid:12544890 |
Furukawa H et al. | Prolongation of canine liver allograft survival by a novel immunosuppressant, FTY720: effect of monotherapy and combined treatment with conventional drugs. | 2000 | Transplantation | pmid:10670633 |
Furukawa H et al. | The effect of bile duct ligation and bile diversion on FK506 pharmacokinetics in dogs. | 1992 | Transplantation | pmid:1373531 |
Ravindran VK et al. | Insulin hyposecretion in nondiabetic, tacrolimus-treated renal transplant recipients more than 6 months posttransplantation. | 2009 | Transplantation | pmid:19543067 |
Maruyama M et al. | Effect of FK506 treatment on allocytolytic T lymphocyte induction in vivo: differential effects of FK506 on L3T4+ and Ly2+ T cells. | 1990 | Transplantation | pmid:1696410 |
Toso C et al. | Insulin independence after conversion to tacrolimus and sirolimus-based immunosuppression in islet-kidney recipients. | 2003 | Transplantation | pmid:14557767 |
Vu MD et al. | Combination therapy of malononitrilamide FK778 with tacrolimus on cell proliferation assays and in rats receiving renal allografts. | 2003 | Transplantation | pmid:12792496 |
Pirsch JD et al. | A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. | 1997 | Transplantation | pmid:9112351 |
Tanabe M et al. | Combined immunosuppressive therapy with low dose FK506 and antimetabolites in rat allogeneic heart transplantation. | 1994 | Transplantation | pmid:7518619 |
Khanna AK | Mechanism of the combination immunosuppressive effects of rapamycin with either cyclosporine or tacrolimus. | 2000 | Transplantation | pmid:10972232 |
Königsrainer A et al. | Nonocclusive segmental mesenteric ischemia after combined pancreas kidney transplantation: mycophenolate mofetil as an etiological factor? | 2000 | Transplantation | pmid:10972233 |
Butani L et al. | Amelioration of tacrolimus-induced nephrotoxicity in rats using juniper oil. | 2003 | Transplantation | pmid:12883183 |
Marcén R et al. | Lumbar bone mineral density in renal transplant patients on neoral and tacrolimus: a four-year prospective study. | 2006 | Transplantation | pmid:16570003 |
Ciancio G et al. | A randomized long-term trial of tacrolimus/sirolimus versus tacrolimums/mycophenolate versus cyclosporine/sirolimus in renal transplantation: three-year analysis. | 2006 | Transplantation | pmid:16570006 |
Sood P et al. | Management and outcome of BK viremia in renal transplant recipients: a prospective single-center study. | 2012 | Transplantation | pmid:23018881 |
Alonso-Arias R et al. | CD127(low) expression in CD4+CD25(high) T cells as immune biomarker of renal function in transplant patients. | 2009 | Transplantation | pmid:19667968 |
Galliford J et al. | ABO incompatible living renal transplantation with a steroid sparing protocol. | 2008 | Transplantation | pmid:18852653 |
Jevnikar A et al. | Five-year study of tacrolimus as secondary intervention versus continuation of cyclosporine in renal transplant patients at risk for chronic renal allograft failure. | 2008 | Transplantation | pmid:18852662 |
Dickenmann MJ et al. | Blood eosinophilia in tacrolimus-treated patients: an indicator of Pneumocystis carinii pneumonia. | 1999 | Transplantation | pmid:10589963 |
Eckhoff DE et al. | Tacrolimus (FK506) and mycophenolate mofetil combination therapy versus tacrolimus in adult liver transplantation. | 1998 | Transplantation | pmid:9458011 |
Naesens M and Sarwal MM | Monitoring calcineurin inhibitor therapy: localizing the moving target. | 2010 | Transplantation | pmid:20458272 |
Kaufman DB et al. | The successful use of tacrolimus (FK506) in a pancreas/kidney transplant recipient with recurrent cyclosporine-associated hemolytic uremic syndrome. | 1995 | Transplantation | pmid:7541579 |
Herlenius G et al. | Chronic kidney disease--a common and serious complication after intestinal transplantation. | 2008 | Transplantation | pmid:18622286 |
Ceulemans LJ et al. | Nonsteroidal anti-inflammatory drug-induced intestinal graft loss 12 years after transplantation. | 2015 | Transplantation | pmid:25695790 |
Thorp M et al. | The effect of conversion from cyclosporine to tacrolimus on gingival hyperplasia, hirsutism and cholesterol. | 2000 | Transplantation | pmid:10762229 |
Fujii Y et al. | Effect of a novel immunosuppressive agent, FK506, on mitogen-induced inositol phospholipid degradation in rat thymocytes. | 1989 | Transplantation | pmid:2472025 |
Amundsen R et al. | Rimonabant affects cyclosporine a, but not tacrolimus pharmacokinetics in renal transplant recipients. | 2009 | Transplantation | pmid:19384170 |
Jun KR et al. | Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea. | 2009 | Transplantation | pmid:19384171 |
Ji E et al. | Combinational effect of intestinal and hepatic CYP3A5 genotypes on tacrolimus pharmacokinetics in recipients of living donor liver transplantation. | 2012 | Transplantation | pmid:22992768 |
Tamura K et al. | Transcriptional inhibition of insulin by FK506 and possible involvement of FK506 binding protein-12 in pancreatic beta-cell. | 1995 | Transplantation | pmid:7539960 |
Fisher A et al. | FK506 hepatotoxicity in liver allograft recipients. | 1995 | Transplantation | pmid:7539961 |
Fukushima D et al. | Epstein-Barr virus--associated posttransplantation lymphoproliferative disorder with tacrolimus metabolism deterioration in infants after living-donor liver transplantation. | 2015 | Transplantation | pmid:24846306 |
Valdivia LA et al. | Dendritic cell replacement in long-surviving liver and cardiac xenografts. | 1993 | Transplantation | pmid:7689265 |
Wang K et al. | Transplantation of infantile bladder in rats: an alternative procedure for bladder augmentation. | 2001 | Transplantation | pmid:11213059 |
Egli A et al. | Comparison of the effect of standard and novel immunosuppressive drugs on CMV-specific T-cell cytokine profiling. | 2013 | Transplantation | pmid:23274966 |
Wennberg L et al. | The efficacy of CD40 ligand blockade in discordant pig-to-rat islet xenotransplantation is correlated with an immunosuppressive effect of immunoglobulin. | 2005 | Transplantation | pmid:15665763 |
Hebert MF et al. | Interpreting tacrolimus concentrations during pregnancy and postpartum. | 2013 | Transplantation | pmid:23274970 |
Gruessner RW et al. | Donor-specific portal blood transfusion in intestinal transplantation: a prospective, preclinical large animal study. | 1998 | Transplantation | pmid:9701258 |
Vathsala A et al. | The immunosuppressive antagonism of low doses of FK506 and cyclosporine. | 1991 | Transplantation | pmid:1713361 |
Thai NL et al. | Alemtuzumab induction and tacrolimus monotherapy in pancreas transplantation: One- and two-year outcomes. | 2006 | Transplantation | pmid:17198247 |
Kawano K et al. | A protective effect of FK506 in ischemically injured rat livers. | 1991 | Transplantation | pmid:1713362 |
Thai NL et al. | Pancreas transplantation under alemtuzumab (Campath-1H) and tacrolimus: Correlation between low T-cell responses and infection. | 2006 | Transplantation | pmid:17198253 |
Konrad T et al. | Regulation of glucose tolerance in patients after liver transplantation: impact of cyclosporin versus tacrolimus therapy. | 2000 | Transplantation | pmid:10852599 |
Lake JR et al. | The impact of immunosuppressive regimens on the cost of liver transplantation--results from the U.S. FK506 multicenter trial. | 1995 | Transplantation | pmid:7482713 |
Aisa Y et al. | Effects of immunosuppressive agents on magnesium metabolism early after allogeneic hematopoietic stem cell transplantation. | 2005 | Transplantation | pmid:16278584 |
Wang HD et al. | Desensitization and Prevention of Antibody-Mediated Rejection in Vascularized Composite Allotransplantation by Syngeneic Hematopoietic Stem Cell Transplantation. | 2018 | Transplantation | pmid:29298238 |
Vadivel N et al. | Tacrolimus dose in black renal transplant recipients. | 2007 | Transplantation | pmid:17460575 |